Compare Novo Nordisk A/S (NVO) vs YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF (QDTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF — how do they compare? Novo Nordisk A/S trades at $46.52 (market cap $207.85B), while YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF trades at $39.7. The key difference: Novo Nordisk A/S pays a 3.81% dividend while YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF pays none. Which is the better fit depends on your goals.
| NVO | QDTY | |
|---|---|---|
Market Cap | $207.85B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $63.98 | $46.71 |
52-Week Low | $35.29 | $36.57 |
Enterprise Value | $222.55B | — |
Dividend Yield | 3.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
QDTY trades at $39.61, down 0.48% with neutral technical signals. The stock shows consistent weekly dividend distributions averaging $0.26-0.30 per share throughout 2026. Technical indicators suggest a balanced market with RSI at neutral levels and bearish moving average signals. Support and resistance cluster around $39-40, indicating tight trading range consolidation.
The outlook remains balanced with dividend income providing stability, though limited fundamental data availability warrants caution. Key risks include market volatility and dependency on ETF distribution strategies. The stock's performance hinges on broader market trends and YieldMax's distribution management effectiveness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF
QDTY is an actively managed ETF that employs a synthetic covered call strategy on the Nasdaq-100 Index using zero-days-to-expiration (0DTE) options. It aims to generate high weekly income by selling daily call options, providing limited participation in the index's upside while remaining fully exposed to its downside risk.
Read more on QDTY →
